Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function

Ipatasertib is a highly selective small‐molecule pan‐Akt inhibitor in clinical development. Ipatasertib is predominantly eliminated by the liver, and therefore, the effect of hepatic impairment on ipatasertib pharmacokinetics (PK) was evaluated. In this phase 1 open‐label, parallel group study, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sane, Rucha, Malhi, Vikram, Sutaria, Dhruvitkumar S, Cho, Eunpi, Twomey, Patrick, Craggs, Christopher, Wang, Jianshuang, Harris, Adam, Musib, Luna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303630/
https://www.ncbi.nlm.nih.gov/pubmed/34402068
http://dx.doi.org/10.1002/jcph.1941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303630/
https://www.ncbi.nlm.nih.gov/pubmed/34402068
http://dx.doi.org/10.1002/jcph.1941

Ejemplares similares